InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INM InMed Pharmaceuticals Inc

Closed Independence Day 07-02 16:00:00 EDT

1.56

-0.03

-1.89%

盘后1.50

-0.06-4.04%

18:08 EDT

High1.60	Low1.55	Vol33.20K
Open1.58	D1 Closing1.59	Amplitude3.14%
Mkt Cap5.17M	Tradable Cap3.37M	Total Shares3.31M
T/O52.18K	T/O Rate1.54%	Tradable Shares2.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INM","market":"US","secType":"STK","nameCN":"InMed Pharmaceuticals Inc","latestPrice":1.56,"timestamp":1783022400000,"preClose":1.59,"halted":0,"volume":33198,"hourTrading":{"tag":"盘后","latestPrice":1.4969,"preClose":1.56,"latestTime":"18:08 EDT","volume":104,"amount":155.93,"timestamp":1783030136929,"change":-0.0631,"changeRate":-0.040449,"amplitude":0.040449},"delay":0,"changeRate":-0.018867924528301903,"floatShares":2159000,"shares":3314100,"eps":-2.532377,"marketStatus":"Closed Independence Day","change":-0.03,"latestTime":"07-02 16:00:00 EDT","open":1.58,"high":1.6,"low":1.55,"amount":52176.167868,"amplitude":0.031447,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.532377,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1783324800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.59,"preHourTrading":{"tag":"盘前","latestPrice":1.56,"preClose":1.59,"latestTime":"09:28 EDT","volume":6,"amount":9.3788994,"timestamp":1782998896094,"change":-0.03,"changeRate":-0.018868,"amplitude":0.011887},"postHourTrading":{"tag":"盘后","latestPrice":1.4969,"preClose":1.56,"latestTime":"18:08 EDT","volume":104,"amount":155.93,"timestamp":1783030136929,"change":-0.0631,"changeRate":-0.040449,"amplitude":0.040449},"volumeRatio":0.723747},"requestUrl":"/m/hq/s/INM/tweets","defaultTab":"tweets","newsList":[{"id":"2648663919","title":"Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648663919","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2648663919?lang=en_us&edition=fundamental","pubTime":"2026-07-03 07:02","pubTimestamp":1783033374,"startTime":"0","endTime":"0","summary":"Vivo Opportunity reports $9,963 purchase of InMed Pharma common sharesVivo Opportunity, a 10% owner of InMed Pharmaceuticals, reported open-market purchases of common shares around USD 1.54–1.55.Vivo ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDLbTGNYb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivo Opportunity Reports $9,963 Purchase of Inmed Pharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642194477","title":"Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642194477","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642194477?lang=en_us&edition=fundamental","pubTime":"2026-06-11 09:15","pubTimestamp":1781140534,"startTime":"0","endTime":"0","summary":"Vivo Opportunity, a 10% owner, boosted its stake in InMed Pharmaceuticals through open-market purchases.Vivo Opportunity Fund Holdings reported 718,444 common shares beneficially owned following the trades.Vivo Opportunity Cayman Fund reported 72,535 common shares beneficially owned following the trades.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL3nSJV0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vivo Opportunity reports $371,785 purchase of InMed Pharma common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642477191","title":"InMed Pharmaceuticals files Form 3 as Vivo Opportunity discloses beneficial ownership of 541,752 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2642477191","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642477191?lang=en_us&edition=fundamental","pubTime":"2026-06-11 09:15","pubTimestamp":1781140510,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals Form 3 disclosed Vivo Opportunity entities as new 10% owners, reporting beneficial ownership as of May 19, 2026.Holdings totaled 541,752 common shares held indirectly through Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nNDL9gwrmt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642447638","title":"InMed Pharmaceuticals regains Nasdaq compliance on $1 minimum bid price rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2642447638","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642447638?lang=en_us&edition=fundamental","pubTime":"2026-06-10 18:04","pubTimestamp":1781085863,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals regained compliance with Nasdaq’s $1 minimum bid price rule, removing a continued-listing risk for its shares.Nasdaq determined the stock closed at or above $1 for 10 consecutive business days from May 19 to June 2.The company had received a Nasdaq notice on March 27 for failing to meet the $1 threshold for 30 straight business days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL8xKCnZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641160112","title":"InMed regains compliance with Nasdaq continued listing requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2641160112","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641160112?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:45","pubTimestamp":1780609511,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) announced that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inmed-regains-compliance-with-nasdaq-continued-listing-requirements-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inmed-regains-compliance-with-nasdaq-continued-listing-requirements-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INM","BK4007","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640064940","title":"InMed Pharma releases INM-089 age-related macular degeneration presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2640064940","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640064940?lang=en_us&edition=fundamental","pubTime":"2026-06-03 02:51","pubTimestamp":1780426281,"startTime":"0","endTime":"0","summary":"InMed published a medical research presentation outlining INM-089, a preclinical cannabinoid analog program for age-related macular degeneration.Asset positioned for divestiture following a merger announcement; InMed flagged openness to multiple transaction structures.Preclinical data cited retinal neuroprotection in an in vivo rat AMD model, including preserved retinal function and improved retinal structure measures.Development plan targets an intravitreal injection product, with pre-IND work, IND-enabling GLP studies, then Phase 1.Patent portfolio highlighted with earliest potential expiries of 2039, 2040, 2043 across composition, use, and manufacturing process filings.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDL8MpYCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637343357","title":"ADAR1 Capital Management acquires 468,551 InMed common shares worth $742,290","url":"https://stock-news.laohu8.com/highlight/detail?id=2637343357","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637343357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397727,"startTime":"0","endTime":"0","summary":"ADAR1 Capital Management, a 10% owner of InMed Pharmaceuticals, reported buying 468,551 common shares.Indirect holdings rose to 800,000 common shares following the purchases.Purchases were reported at weighted average prices of $1.6, $1.56, and $1.5.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL2rn0n0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ADAR1 Capital Management acquires 468,551 InMed common shares worth $742,290","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352113","title":"InMed Pharmaceuticals files Form 3 showing ADAR1 Capital Management stake of 331,449 shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352113","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352113?lang=en_us&edition=fundamental","pubTime":"2026-05-22 04:51","pubTimestamp":1779396705,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals reported ADAR1 Capital Management as a 10% owner in an initial beneficial ownership filing dated May 19, 2026.The filing shows 331,449 common shares held indirectly through private investment funds managed by ADAR1.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL9N071s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636586868","title":"BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy","url":"https://stock-news.laohu8.com/highlight/detail?id=2636586868","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636586868?lang=en_us&edition=fundamental","pubTime":"2026-05-19 23:48","pubTimestamp":1779205729,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy  Workspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newslett","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nL6N41W134:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMST","CVNA","XE","CRM","NVD3.UK","ALB","DRVN","GOOX","KR","WOK","NVDW","BX","NVD2.UK","NVDQ","HD","CRMG","BDX","2NVD.UK","HIMS","GGLL","VRT","TE","HIYY","HIMZ","RLAY","YMAT","GOOY","HMYY","CODX","VPG","DIPS","SITM","AS","ONTO","SKLZ","NOW","HIMY","GOOW","GOOGL","WNW","HSBA.UK","NVDA","GOU","INM","NVDS.UK","INTU","WDAY","ONCO","HOTH","CTRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636545438","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636545438","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636545438?lang=en_us&edition=fundamental","pubTime":"2026-05-19 21:42","pubTimestamp":1779198151,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 09:42 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nAQN2LZNLF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636855461","title":"InMed Pharmaceuticals agrees to all-stock merger with Mentari Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2636855461","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636855461?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:02","pubTimestamp":1779192159,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals reached a definitive all-stock merger agreement with privately held Mentari Therapeutics, combining Mentari’s migraine-prevention pipeline with InMed’s public listing.The combined company is expected to operate as Mentari Therapeutics, remaining listed on the Nasdaq Capital Market under a new ticker symbol.Mentari also completed an oversubscribed US$ 290 million private placement intended to fund operations through 2028.First-in-human regulatory filings are expected in mid-2026 for MT-001, an anti-PACAP antibody, followed by 1Q 2027 for MT-002, an anti-CGRP x PACAP bispecific antibody.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL54Sk6l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885511","title":"InMed Pharmaceuticals: InMed Shareholders Are Expected to Own Approximately 1.51% of Combined Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885511","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885511?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W068:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636437855","title":"InMed Pharmaceuticals: Post Deal, Combined Company to Have Pro Forma Equity Value of About US$421.4 Mln (Inclusive of Private Placement)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636437855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636437855?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192009,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nFWN41W068:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636551548","title":"Press Release: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2636551548","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636551548?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:00","pubTimestamp":1779192000,"startTime":"0","endTime":"0","summary":"Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapies. Concurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028. First-in-human regulatory filings for MT-001  and MT-002  expected mid-2026 and 1Q 2027, respectively. Conference call scheduled for May 19, 2026, at 8:30 AM EDT. VANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc.   is pleased to announce that it has entered into a definitive merger agreement  for an all-stock transaction with Mentari Therapeutics, Inc. , a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. The merger brings together Mentari's differentiated migraine pipeline with InMed's public","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","LENZ","INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636985559","title":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2636985559","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636985559?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:55","pubTimestamp":1779191700,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  HALT NEWS PENDING AT 07:55 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nAQN2LZKTE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633163279","title":"InMed net loss widens 40% to USD 2.97 million in Q3 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2633163279","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633163279?lang=en_us&edition=fundamental","pubTime":"2026-05-07 06:12","pubTimestamp":1778105558,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals posted a net loss of USD 2.97 million for the quarter ended March 31, 2026, widening 40%.Net loss from continued operations widened to USD 2.79 million, while operating expenses rose 36% to USD 2.84 million.Research and development expense more than doubled to USD 1.02 million, while general and administrative costs increased 10% to USD 1.74 million.Cash, cash equivalents, and short-term investments totaled USD 5.2 million as of March 31, 2026, with management expecting funding into the fourth quarter of calendar 2026 and flagging substantial doubt about going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL7xwKZY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631682987","title":"FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification","url":"https://stock-news.laohu8.com/highlight/detail?id=2631682987","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631682987?lang=en_us&edition=fundamental","pubTime":"2026-04-30 18:00","pubTimestamp":1777543200,"startTime":"0","endTime":"0","summary":"FOCUS-Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassificationExecutives say stigma reduction and eased banking rules may attract mainstream investorsRescheduling ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nL4N3XO13Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823416689.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU0154245673.USD","IE00BN0W2W23.USD","LU0889565916.HKD","BK4104","BK4532","BK4533","LU0109394709.USD","LU0320765992.SGD","IGC","LU0154245756.USD","INM","JAZZ","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624966455","title":"InMed Pharmaceuticals files prospectus supplement for at-the-market common share offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2624966455","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624966455?lang=en_us&edition=fundamental","pubTime":"2026-04-04 04:20","pubTimestamp":1775247609,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals filed prospectus supplement to sell common shares under its at-the-market equity distribution agreement with H.C. Wainwright.Offering uses shelf registration statement on Form S-3 filed March 20, 2026.SEC declared registration statement effective March 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL8drGbl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623634477","title":"InMed receives Nasdaq notification regarding minimum bid price compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2623634477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623634477?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:22","pubTimestamp":1774884131,"startTime":"0","endTime":"0","summary":"InMed Pharmaceuticals (INM) announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market d...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/inmed-receives-nasdaq-notification-regarding-minimum-bid-price-compliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/inmed-receives-nasdaq-notification-regarding-minimum-bid-price-compliance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","BK4007","INM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622435803","title":"InMed Pharmaceuticals drops on Nasdaq notice; bid price stays below $1.00 for 30 straight sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2622435803","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622435803?lang=en_us&edition=fundamental","pubTime":"2026-03-28 05:05","pubTimestamp":1774645539,"startTime":"0","endTime":"0","summary":"InMed received a Nasdaq notice stating its shares failed to meet the minimum bid price requirement of $1.00 for continued listing on the Nasdaq Capital Market.The notice said the closing bid price was below $1.00 for 30 consecutive trading days during the February 11, 2026 to March 26, 2026 period.Nasdaq rules provide a 180-day compliance period, and InMed must have a closing bid price at or above $1.00 for at least 10 consecutive business days to regain compliance.If compliance is not regained, the company may qualify for an additional 180-day period and may need to consider a reverse stock split to cure the deficiency.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL86vyjl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INM","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.inmedpharma.com","stockEarnings":[{"period":"1week","weight":0.0331},{"period":"1month","weight":0.0263},{"period":"3month","weight":1.3009},{"period":"6month","weight":0.3929},{"period":"1year","weight":-0.4885},{"period":"ytd","weight":0.4717}],"compareEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.0195},{"period":"3month","weight":0.1356},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2004},{"period":"ytd","weight":0.0922}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.055524},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.102625},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.177592},{"month":4,"riseRate":0.666667,"avgChangeRate":0.079677},{"month":5,"riseRate":0.5,"avgChangeRate":0.150541},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.071204},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.111403},{"month":8,"riseRate":0.2,"avgChangeRate":0.013552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.118637},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198876},{"month":11,"riseRate":0.2,"avgChangeRate":-0.092328},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.132014}],"exchange":"NASDAQ","name":"InMed Pharmaceuticals Inc","nameEN":"InMed Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"InMed Pharmaceuticals Inc,INM,InMed Pharmaceuticals Inc股票,InMed Pharmaceuticals Inc股票老虎,InMed Pharmaceuticals Inc股票老虎国际,InMed Pharmaceuticals Inc行情,InMed Pharmaceuticals Inc股票行情,InMed Pharmaceuticals Inc股价,InMed Pharmaceuticals Inc股市,InMed Pharmaceuticals Inc股票价格,InMed Pharmaceuticals Inc股票交易,InMed Pharmaceuticals Inc股票购买,InMed Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"InMed Pharmaceuticals Inc(INM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest InMed Pharmaceuticals Inc(INM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction